

**VI. Claim Amendments under 37 C.F.R. § 1.121**

1. (Currently amended) A composition comprising at least two isolated immunogenic ligands, wherein each said immunogenic ligands are individually characterized by an ability to elicit an immune response against the same native ligand, and wherein said immunogenic ligand is selected from the group consisting of FLQLLMEPV (SEQ ID NO:3), FLQLEFDAV (SEQ ID NO:5), FLWFEIDIV (SEQ ID NO:7), FLSYDLFVV (SEQ ID NO:9), and NLQLLMDRV (SEQ ID NO:11).
2. (Original) The composition of claim 1, further comprising a carrier.
3. (Original) The composition of claim 2, wherein the carrier is a pharmaceutically accepted carrier.
4. (Withdrawn) A host cell comprising at least two immunogenic ligands, wherein said immunogenic ligands are individually characterized by an ability to elicit an immune response against the same native ligand, and wherein said immunogenic ligand is selected from the group consisting of FLQLLMEPV (SEQ ID NO:3), FLQLEFDAV (SEQ ID NO:5), FLWFEIDIV (SEQ ID NO:7), FLSYDLFVV (SEQ ID NO:9), and NLQLLMDRV (SEQ ID NO:11).
5. (Withdrawn) The host cell of claim 4, wherein the host cell is an antigen presenting cell and the immunogenic ligands are presented on the surface of the cell.
6. (Withdrawn) The host cell of claim 5, wherein the antigen presenting cell is a dendritic cell.
7. (Withdrawn) A composition comprising the host cell of any of claims 4 to 6 and a carrier.
8. (Withdrawn) The composition of claim 7, wherein the carrier is a pharmaceutically accepted carrier.
9. (Currently amended) A method for inducing an immune response in a subject, comprising delivering to a subject a composition comprising an effective amount of two or more immunogenic ligands, wherein ~~each of said immunogenic ligands is characterized by an ability to elicit an immune response against the same native ligand, and wherein~~ each said immunogenic ligand is selected from the group consisting of FLQLLMEPV (SEQ ID NO:3), FLQLEFDAV (SEQ ID NO:5), FLWFEIDIV (SEQ ID NO:7), FLSYDLFVV (SEQ ID NO:9), and NLQLLMDRV (SEQ ID NO:11).

10. (New) A composition comprising an isolated ligand, wherein said ligand is selected from the group consisting of FLQLLMEPV (SEQ ID NO:3), FLQLEFDAV (SEQ ID NO:5), FLWFEIDIV (SEQ ID NO:7), and FLSYDLFVV (SEQ ID NO:9).

11. (New) The composition of claim 10, wherein said composition further comprises SEQ ID NO: 11.

12. (New) A composition comprising an isolated ligand consisting of SEQ ID NO: 11.

13. (New) A method to generate antigen-specific immune effector cells comprising

a) delivering a ligand composition of claim 1, 10, or 11 to an antigen presenting cell, wherein said antigen presenting cell presents at least one ligand from said composition, and

b) mixing said antigen presenting cells with naive immune effector cells, wherein said immune effector cells proliferate and become antigen-specific at the expense of said antigen presenting cells.

14. (New) The composition of immune effector cells generated in claim 13.

15. (New) The method of claim 13, wherein the antigen presenting cell is a dendritic cell.

16. (New) The composition of claim 14, wherein the immune effector cells are T cells.